阿帕替尼在恶性肿瘤治疗中的应用研究进展

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (0 KB) HTML (40 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来，分子靶向治疗在恶性肿瘤治疗中的应用迅速增多，被认为是一种有效地治疗恶性肿瘤的方式。肿瘤新生血管生成与肿瘤生长、转移密切相关，其中血管内皮生长因子及其受体起着重要作用。甲磺酸阿帕替尼是一种新型的抗血管生成药物，通过高度选择性地结合并抑制血管内皮生长因子-2（VEGF-2），而抑制肿瘤血管生成，抑制肿瘤生长。甲磺酸阿帕替尼在胃癌、非小细胞肺癌的几项临床研究中有可观的客观有效率及生存获益，2014年已批准其用于晚期胃癌的治疗，目前关于阿帕替尼治疗胃癌、肺癌、结直肠癌等多种肿瘤的临床研究正在积极开展，希望能为恶性肿瘤的治疗提供新的选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	左权
	向志碧

关键词 ：甲磺酸阿帕替尼, 恶性肿瘤, 抗血管生成, 血管内皮生长因子

Abstract：In recent years, the application of molecular targeting therapy in the treatment of malignant tumors has increased rapidly, which is considered to be an effective way to treat malignant tumors.Vascular endothelial growth factor and its receptors play important roles in tumor neovascularization,which is closely related to tumor growth and metastasis.Apatinib Mesylate is a new type of anti-angiogenic drug, which can inhibit tumor angiogenesis and the growth of tumor by highly selective binding and inhibition of vascular endothelial growth factor-2 (VEGF-2).Apatinib Mesylate has considerable objective response rate and survival benefit in several clinical studies of gastric cancer and non-small cell lung cancer and has been approved for the treatment of advanced gastric cancer in 2014.At present, the clinical researches on Apatinib in the treatment of gastric cancer, lung cancer, colorectal cancer and other tumors are being actively carried out, which is hoping to provide a new choice for the treatment of malignant tumors.

Key words： Apatinib Mesylate Malignant tumor Antiangiogenic Vascular endothelial growth factor

引用本文:

左权；向志碧. 阿帕替尼在恶性肿瘤治疗中的应用研究进展[J]. 中国当代医药, 2020, 27(3): 17-20.
ZUO Quan； XIANG Zhi-bi. Research advances of Apatinib in the treatment of malignant tumor. 中国当代医药, 2020, 27(3): 17-20.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I3/17

[26]	马兴群，成远，陈映霞.VEGF 信号通路抑制剂相关蛋白尿的研究进展[J].临床肿瘤学杂志，2015，20（4）：357-362.
[1]	Torre LA，Bray F，Siegel RL，et al.Global cancer statistics，2012[J].CA Cancer J Clin，2015，65（2）：87-108.
[2]	Tian S，Quan H，Xie C，et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci，2011，102（7）：1374-1380.
[3]	Scott AJ，Messersmith WA，Jimeno A.Apatinib：a promising oral antiangiogenicagent in the treatment of multiple solid tumors[J].Drugs Today（Barc），2015，51（4）：223-229.
[4]	Li J，Qin S，Xu J，et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer： results from a randomized，placebo-controlled，parallel-arm，phase Ⅱtrial[J].J Clin Oncol，2013，31（26）：3219-3225.
[6]	秦叔逵，李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志，2015，20（9）：841-847.
[10]	Hu X，Cao J，Hu W，et al.Multicenter phase Ⅱstudy of Apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer，2014，14：820.
[14]	马国军，杜可，李涛，等.甲磺酸阿帕替尼治疗晚期食管鳞癌临床观察[J].中华肿瘤防治杂志，2019，26（4）：250-254.
[22]	Rini BI.Biomarkers：hypertension following anti-angiogenesis therapy[J].Clin Adv Hematol Oncol，2010，8（6）：415-416.
[5]	Li J，Qin S，Xu J，et al.Randomized，double-Blind，placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol，2016，34（13）：1448-1454.
[7]	Guo Y，Tang J，Huang X E，et al.Efficacy and toxicity of Apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma：A prospective clinical study[J].Medicine，2019，98（6）：e13908.
[8]	Liu Y，Zhou C，Zhang K，et al.The combination of Apatinib and S-1 for the treatment of advanced gastric cancer in China： A meta-analysis of randomized controlled trials[J].Medicine，2018，97（47）：e13259.
[9]	Zhang L，Shi M，Huang C，et al.A phase Ⅱ，multicenter，placebo-controlled trial of Apatinib in patients with advanced nonsquamous non-small cell lung cancer（NSCLC）after two previous treatment regimens[J].J Clin Oncol，2012，30（15）：7548.
[11]	Hu X，Zhang J，Xu B，et al.Multicenter phase Ⅱstudy of Apatinib，a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].Int J Cancer，2014，135（8）：1961-1969.
[12]	Yu WC，Zhang KZ，Chen SG，et al.Efficacy and safety of Apatinib in patients with intermediate/advanced hepatocellular carcinoma：A prospective observation study[J].Medicine，2018，97（3）：e9704.
[13]	Chen S，Yu W，Zhang K，et al.Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma[J].BMC Cancer，2018，18（1）：1131.
[15]	Miao M，Deng G，Luo S，et al.A phase Ⅱstudy of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol，2018，148（2）：286-290.
[16]	Lan CY，Wang Y，Xiong Y，et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer（AEROC）：a phase 2，singlearm，prospective study[J].Lancet Oncol，2018，19（9）：1239-1246.
[17]	Tian Z，Gu Z，Wang X，et al.Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy：An observational study[J].Medicine，2019，98（19）：e15650.
[30]	邹文，李晓梅，王荣梅.阿帕替尼联合应用替吉奥致严重皮下出血及皮肤破溃1 例[J].中国新药与临床杂志，2017，36（3）：176-179.
[18]	Zheng K，Xu M，Wang L，et al.Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases：A single-center observational study[J].Medicine，2018，97（31）：e11734.
[19]	Li J，Zhao X，Chen L，et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer，2010，10：529.
[20]	Roviello G，Pacifico C，Corona P，et al.Risk of hypertension with ramucirumab-based therapy in solid tumors：data from a literature based meta-analysis[J].Invest New Drugs，2017，35（4）：518-523.
[21]	Mariëtte Hw Kappers，Esch JHMW，Sleijfer S，et al.Cardiovascular and renal toxicity during angiogenesis inhibition：clinical and mechanistic aspects[J].J Hypertens，2009，27（12）：2297-2309.
[23]	Tang JR，Markham NE，Lin YJ，et al.Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor[J].Am J Physiol Lung Cell Mol Physiol，2004，287（2）：L344-L351.
[24]	Syrigos KN，Karapanagiotou E，Boura P，et al.Bevacizumab-induced hypertension：pathogenesis and management[J].Bio Drugs，2011，25（3）：159-169.
[25]	Eremina V，Baelde HJ，Quaggin SE.Role of the VEGF-a signaling pathway in the glomerulus：evidence for crosstalk between components of the glomerular filtration barrier[J].Nephron Physiol，2007，106（2）：32-37.
[27]	Degen A，Alter M，Schenck F，et al.The hand-foot-syndrome associated with medical tumor therapy-classification and management[J].J Dtsch Dermatol Ges，2010，8（9）：652-661.
[28]	Belum VR，Wu S，Lacouture ME.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib：a meta-analysis[J].Invest New Drugs，2013，31（4）：1078-1086.
[29]	Li XF，Tan YN，Cao Y，et al.A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer[J].Medicine，2015，94（39）：e1661.